ADMA Biologics Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $60.12M Beat $55.50M Estimate
Portfolio Pulse from mahesh@benzinga.com
ADMA Biologics reported Q2 losses of $(0.03) per share, missing the analyst consensus estimate of $(0.02) by 50%. However, the company's quarterly sales of $60.12 million beat the estimate of $55.50 million by 8.33%. This represents a 57.14% increase in losses and a 77.33% increase in sales compared to the same period last year.
August 09, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ADMA Biologics reported a larger than expected loss for Q2, but exceeded sales estimates. This mixed result could lead to uncertainty in the market.
ADMA Biologics reported a larger loss than expected, which could negatively impact the stock. However, the company also reported higher than expected sales, which could have a positive impact. The mixed results could lead to uncertainty in the market, making it difficult to predict the short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100